North Central Cancer Treatment Group Phase II study of 5-fluorouracil and high-dose levamisole for gastric and gastroesophageal cancer using survival as the primary endpoint of efficacy.

Burch, P A; Keppen, M D; Schroeder, G; Rubin, J; Krook, J E; Dalton, R J; Gerstner, J B; Jancewicz, M T; Ebbert, L P

Burch, P A; Keppen, M D; Schroeder, G; Rubin, J; Krook, J E; Dalton, R J; Gerstner, J B; Jancewicz, M T; Ebbert, L P.

Affiliation

Burch PA; Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.

Am J Clin Oncol ; 22(5): 505-8, 1999 Oct.

Article in En | MEDLINE | ID: mdl-10521068

Subject(s)

Adenocarcinoma/drug therapy; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Esophageal Neoplasms/drug therapy; Stomach Neoplasms/drug therapy; Adenocarcinoma/mortality; Adult; Aged; Aged, 80 and over; Esophageal Neoplasms/mortality; Female; Fluorouracil/administration & dosage; Humans; Levamisole/administration & dosage; Male; Middle Aged; Stomach Neoplasms/mortality; Survival Rate; United States/epidemiology

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Stomach Neoplasms / Esophageal Neoplasms / Adenocarcinoma / Antineoplastic Combined Chemotherapy Protocols Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Am J Clin Oncol Year: 1999 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links